drugset / Trial / NCT03286218

A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users

NCT03286218

Phase 1 Completed 96 enrolled Eli Lilly and Company
RandomizedCrossoverDouble-blindBasic science

Summary

The purpose of this study is to assess the abuse potential of study drug lasmiditan. Lasmiditan will be compared to a marketed benzodiazepine, alprazolam (positive control), as well as to placebo (dummy substance that looks like lasmiditan or alprazolam without any active drug) to determine the potential for drug abuse. The dosages will be in tablet form and will be taken orally (by mouth). This study will last about 55 days, including screening. Screening will occur within 28 days prior to qualification phase.

Timeline

Start
2017-09-15
Primary completion
2017-11-20
Completion
2017-11-20

Drugs

EvaluationDrugModalityDoseRoute
Comparator Alprazolam Small molecule 2 mg Oral
Subject Lasmiditan Small molecule 100 mg Oral
Subject Lasmiditan Small molecule 200 mg Oral
Subject Lasmiditan Small molecule 400 mg Oral

Indications